Photocure ASA announced that its partner Asieris Pharmaceuticals has communicated that the multinational Cevira Phase III clinical trial has been completed and successfully met its primary endpoint. Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure. The results of the study will be submitted to the Chinese National Medical Products Administration (NMPA) as part of a new drug application (NDA) in the coming months.

This study is a prospective, randomized, double-blind, placebo-controlled international multicenter Phase III clinical trial designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL. It is led by Academy Member Dr. Jinghe Lang from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and has enrolled 402 participants. The trial met its primary endpoint, together with a robust safety profile.

Comprehensive data from this study will be presented at forthcoming academic conferences and published in scientific journals.